Gritstone bio Stock (NASDAQ:GRTS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.20

52W Range

$0.18 - $3.33

50D Avg

$0.51

200D Avg

$1.28

Market Cap

$22.44M

Avg Vol (3M)

$1.91M

Beta

0.50

Div Yield

-

GRTS Company Profile


Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

231

IPO Date

Sep 28, 2018

Website

GRTS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Collaboration Revenue$300.00K--
License$1.33M$9.27M$46.72M
Grant$15.01M$10.68M$1.50M

Fiscal year ends in Dec 23 | Currency in USD

GRTS Financial Summary


Dec 23Dec 22Dec 21
Revenue$16.34M$9.27M$46.72M
Operating Income$-139.62M$-120.43M$-75.21M
Net Income$-138.49M$-113.13M$-74.95M
EBITDA$-139.62M$-118.45M$-68.86M
Basic EPS-$-1.24$-0.95
Diluted EPS-$-1.24$-0.95

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 09, 24 | 12:00 AM
Q1 23May 11, 23 | 10:42 PM
Q4 22Mar 09, 23 | 10:21 PM

Peer Comparison


TickerCompany
FULCFulcrum Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
ERASErasca, Inc.
ADAPAdaptimmune Therapeutics plc
GBIOGeneration Bio Co.
CRVSCorvus Pharmaceuticals, Inc.
IFRXInflaRx N.V.
GTHXG1 Therapeutics, Inc.
APTOAptose Biosciences Inc.
HRTXHeron Therapeutics, Inc.
SGMOSangamo Therapeutics, Inc.
KRONKronos Bio, Inc.
PASGPassage Bio, Inc.
ALLOAllogene Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
BBIOBridgeBio Pharma, Inc.
ANNXAnnexon, Inc.
AFMDAffimed N.V.
LPTXLeap Therapeutics, Inc.
KZRKezar Life Sciences, Inc.
ANVSAnnovis Bio, Inc.
AUPHAurinia Pharmaceuticals Inc.